RGEN icon

Repligen

147.28 USD
-2.21
1.48%
Updated Feb 12, 1:03 PM EST
1 day
-1.48%
5 days
-9.09%
1 month
-7.04%
3 months
-0.88%
6 months
-9.96%
Year to date
2.96%
1 year
-28.40%
5 years
37.84%
10 years
477.57%
 

About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Employees: 1,783

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

34% more call options, than puts

Call options by funds: $55M | Put options by funds: $40.9M

15% more capital invested

Capital invested by funds: $7.18B [Q2] → $8.28B (+$1.1B) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 154 | Existing positions reduced: 154

10% less first-time investments, than exits

New positions opened: 75 | Existing positions closed: 83

2.45% less ownership

Funds ownership: 101.94% [Q2] → 99.49% (-2.45%) [Q3]

3% less funds holding

Funds holding: 452 [Q2] → 440 (-12) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$165
12%
upside
Avg. target
$173
17%
upside
High target
$180
22%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
42% 1-year accuracy
138 / 331 met price target
22%upside
$180
Buy
Maintained
23 Jan 2025
Canaccord Genuity
Kyle Mikson
46% 1-year accuracy
13 / 28 met price target
12%upside
$165
Hold
Initiated
17 Dec 2024

Financial journalist opinion

Based on 4 articles about RGEN published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Positive
Zacks Investment Research
1 week ago
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now?
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Positive
Zacks Investment Research
2 weeks ago
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
Positive
Zacks Investment Research
4 weeks ago
HRMY or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks?
HRMY or RGEN: Which Is the Better Value Stock Right Now?
Neutral
GlobeNewsWire
1 month ago
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT.
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Repligen Launches the CTech™ SoloVPE® PLUS System
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.
Repligen Launches the CTech™ SoloVPE® PLUS System
Neutral
PRNewsWire
1 month ago
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J.
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
Positive
Zacks Investment Research
2 months ago
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Neutral
GlobeNewsWire
2 months ago
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “Advancing Impacts”, this newly reformatted report streamlines the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2023 Sustainability Report are detailed disclosures aligned with four key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs) and Task Force on Climate-Related Disclosures (TCFD).
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
Neutral
GlobeNewsWire
2 months ago
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
Charts implemented using Lightweight Charts™